Medicine and Dentistry
Pulmonary Hypertension
94%
Chimeric Antigen Receptor
70%
Malignant Neoplasm
65%
Hematologic Malignancy
58%
Immunity
53%
Hospital Mortality
53%
Intensive Care
50%
Sepsis
50%
Intensive Care Unit
50%
Bloodstream Infection
49%
Interstitial Lung Disease
47%
Septic Shock
47%
Cytokine Release Syndrome
43%
Chimeric Antigen Receptor T-Cell
39%
Cell Therapy
35%
Odds Ratio
34%
Deterioration
34%
Oncology
33%
Clinician
31%
Effector Cell
29%
Hematopoietic Stem Cell Transplantation
29%
Fluid Balance
26%
Antibiotic Therapy
26%
Toxicity and Intoxication
24%
Emphysema
23%
Gestational Hypertension
23%
Survival Analysis
23%
Chronic Obstructive Pulmonary Disease
23%
Treprostinil
23%
Silo-Filler's Disease
23%
COVID-19
23%
Bone Marrow Transplantation
23%
Interleukin 6
23%
Acute Respiratory Distress Syndrome
23%
Graft Versus Host Reaction
23%
Stenotrophomonas maltophilia
23%
Receptor Blocking Agent
23%
Secondary Infection
23%
Acute Respiratory Failure
23%
Interleukin 6 Receptor
23%
Patient Registry
23%
Immunotherapy
23%
Heart Function
23%
Checklist
23%
Reuptake Inhibitor
23%
Antidepressant
23%
Serotonin
23%
Chimeric Antigen Receptor T-Cell Immunotherapy
22%
Targeted Therapy
16%
Intensivist
15%
Keyphrases
Pulmonary Arterial Hypertension
100%
Chimeric Antigen Receptor T Cells (CAR-T)
62%
Hematological Malignancies
60%
Hospital Mortality
57%
Cytokine Release Syndrome
56%
Pulmonary Hypertension
54%
Interstitial Lung Disease
50%
Septic Shock
47%
Inhaled Treprostinil
47%
Bloodstream Infection
47%
Selexipag
47%
Critically Ill Patients
45%
Intensive Care Unit
40%
Odds Ratio
39%
Patients with Cancer
37%
Appropriate Antibiotics
36%
Clinical Deterioration
32%
Chimeric Antigen Receptor T-cell Therapy
31%
Critical Care
29%
Confidence Interval
28%
Cell-Associated
27%
Fluid Balance
26%
Neurotoxicity
26%
Sepsis
26%
Clinical Outcomes
25%
Clinical Patients
25%
Interleukin-6 Levels
23%
Pulmonary Graft-versus-host Disease
23%
Emphysema
23%
Acute Respiratory Failure
23%
Toxicity Management
23%
Mechanically Ventilated Patients
23%
Interleukin-6 Inhibitors
23%
Hypertensive Disorders of Pregnancy
23%
Tyvaso
23%
Dry Powder Inhaler
23%
Lung Disease
23%
Infection Prediction
23%
COVID-19
23%
Interleukin-6
23%
Secondary Infection
23%
Acute Respiratory Distress Syndrome
23%
Bone Marrow Transplantation
23%
Antibiotic Coverage
23%
Prediction Score
23%
Patient Registry
23%
Clinical Considerations
23%
Cancer Hospital
23%
Immune Therapy
23%
Process of Care
23%
Pharmacology, Toxicology and Pharmaceutical Science
Pulmonary Hypertension
80%
Treprostinil
70%
Malignant Neoplasm
49%
Chimeric Antigen Receptor
47%
Selexipag
47%
Cytokine Release Syndrome
41%
Hospital Mortality
33%
Toxicity and Intoxication
26%
Diseases
26%
Bloodstream Infection
26%
Interstitial Lung Disease
25%
Interleukin 6 Receptor
23%
Secondary Infection
23%
Coronavirinae
23%
Dry Powder Inhaler
23%
Immunotherapy
23%
Adult Respiratory Distress Syndrome
23%
Interleukin 6
23%
Receptor Blocking Agent
23%
Septic Shock
23%
Macrolide
23%
Survival Rate
23%
Tolerability
23%
Deterioration
23%
Sepsis
23%
Health Care Associated Pneumonia
23%
Macitentan
23%
Antidepressant
23%
Hematologic Malignancy
23%
Serotonin Reuptake Inhibitor
23%
Side Effect
16%
Adverse Event
16%
Antibiotics
15%
Bleeding
15%
Community Acquired Pneumonia
14%
Cohort Study
14%
Infection
13%
Thrombocytopenia
13%
Hypertensive Factor
12%
Comorbidity
10%
Placebo
10%
Long Term Survival
10%
Cytokine
10%
Tocilizumab
10%
Monoclonal Antibody
9%
Prostacyclin
8%
Organ Toxicity
8%
Overall Survival
7%
Neurotoxicity
7%
Hemophagocytic Syndrome
7%
